請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/18831
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 林淑文(Shu-Wen Lin) | |
dc.contributor.author | Wan-Chi Chia | en |
dc.contributor.author | 賈琬琪 | zh_TW |
dc.date.accessioned | 2021-06-08T01:29:24Z | - |
dc.date.copyright | 2020-09-02 | |
dc.date.issued | 2020 | |
dc.date.submitted | 2020-08-11 | |
dc.identifier.citation | 1. Global tuberculosis report 2019. Geneva: World Health Organization; 2019. 2. CDC Annual Report 2019. Centers for Disease Control, Ministry of Health and Welfare, R.O.C.(Taiwan). 3. Efficacy of various durations of isoniazid preventive therapy for tuberculosis: five years of follow-up in the IUAT trial. International Union Against Tuberculosis Committee on Prophylaxis. Bull World Health Organ, 1982. 60(4): p. 555-64. 4. Sterling, T.R., et al., Three months of rifapentine and isoniazid for latent tuberculosis infection. N Engl J Med, 2011. 365(23): p. 2155-66. 5. Villarino, M.E., et al., Treatment for preventing tuberculosis in children and adolescents: a randomized clinical trial of a 3-month, 12-dose regimen of a combination of rifapentine and isoniazid. JAMA Pediatr, 2015. 169(3): p. 247-55. 6. Sterling, T.R., et al., Flu-like and Other Systemic Drug Reactions Among Persons Receiving Weekly Rifapentine Plus Isoniazid or Daily Isoniazid for Treatment of Latent Tuberculosis Infection in the PREVENT Tuberculosis Study. Clin Infect Dis, 2015. 61(4): p. 527-35. 7. Sun, H.Y., et al., Twelve-dose weekly rifapentine plus isoniazid for latent tuberculosis infection: A multicentre randomised controlled trial in Taiwan. Tuberculosis (Edinb), 2018. 111: p. 121-126. 8. Ulrichs, T., S.H.J.T.J.o.P.A.J.o.t.P.S.o.G.B. Kaufmann, and Ireland, New insights into the function of granulomas in human tuberculosis. Journal of Pathology, 2006. 208(2): p. 261-269. 9. Ai, J.-W., et al., Updates on the risk factors for latent tuberculosis reactivation and their managements. Emerging microbes infections, 2016. 5(2): p. e10-e10. 10. Ruhwald, M., et al., Safety and efficacy of the C-Tb skin test to diagnose Mycobacterium tuberculosis infection, compared with an interferon γ release assay and the tuberculin skin test: a phase 3, double-blind, randomised, controlled trial. Lancet Respiratory Medicine, 2017. 5(4): p. 259-268. 11. 衛生福利部疾病管制署. 潛伏結核感染(LTBI). [cited 2020 June 28]; Available from: https://www.cdc.gov.tw/File/Get/BSpCgENxiTLgaTQ8gTrokg. 12. Ji, B., et al., Effectiveness of rifampin, rifabutin, and rifapentine for preventive therapy of tuberculosis in mice. Am Rev Respir Dis, 1993. 148(6 Pt 1): p. 1541-6. 13. Miyazaki, E., R.E. Chaisson, and W.R. Bishai, Analysis of rifapentine for preventive therapy in the Cornell mouse model of latent tuberculosis. Antimicrob Agents Chemother, 1999. 43(9): p. 2126-30. 14. Chapuis, L., et al., Preventive therapy of tuberculosis with rifapentine in immunocompetent and nude mice. American journal of respiratory and critical care medicine, 1994. 150(5): p. 1355-1362. 15. Huang, Y.W., et al., Impacts of 12-dose regimen for latent tuberculosis infection: Treatment completion rate and cost-effectiveness in Taiwan. Medicine (Baltimore), 2016. 95(34): p. e4126. 16. Lee, M.R., et al., Isoniazid Concentration and NAT2 Genotype Predict Risk of Systemic Drug Reactions during 3HP for LTBI. Journal of Clinical Medicine, 2019. 8(6). 17. Evans, D.A.P., K.A. Manley, and V.A. McKusick, Genetic control of isoniazid metabolism in man. British medical journal, 1960. 2(5197): p. 485. 18. Nahid, P., et al., Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis. Clin Infect Dis, 2016. 63(7): p. e147-e195. 19. Borisov, A.S., et al., Update of Recommendations for Use of Once-Weekly Isoniazid-Rifapentine Regimen to Treat Latent Mycobacterium tuberculosis Infection. MMWR Morb Mortal Wkly Rep, 2018. 67(25): p. 723-726. 20. Zhang, Y., et al., The catalase—peroxidase gene and isoniazid resistance of Mycobacterium tuberculosis. Nature, 1992. 358(6387): p. 591. 21. Rozwarski, D.A., et al., Modification of the NADH of the isoniazid target (InhA) from Mycobacterium tuberculosis. Science, 1998. 279(5347): p. 98-102. 22. Grayson, M.L., et al., Kucers' The Use of Antibiotics Sixth Edition: A Clinical Review of Antibacterial, Antifungal and Antiviral Drugs. 2010: CRC Press. 23. Brunton, L.L., B.A. Chabner, and B.C. Knollman, Goodman and Gilman's The Pharmacological Basis of Therapeutics, Twelfth Edition. Chapter 56. 2011, McGraw Hill Professional. 24. Männisto, P., et al., Influence of various diets on the bioavailability of isoniazid. Journal of Antimicrobial Chemotherapy, 1982. 10(5): p. 427-434. 25. Woo, J., et al., In vitro protein binding characteristics of isoniazid, rifampicin, and pyrazinamide to whole plasma, albumin, and alpha-1-acid glycoprotein. Clin Biochem, 1996. 29(2): p. 175-7. 26. Bing, C., C. Xiaomeia, and L. Jinhenga, Gene dose effect of NAT2 variants on the pharmacokinetics of isoniazid and acetylisoniazid in healthy Chinese subjects. Drug Metabolism and Drug Interactions, 2011. 26(3): p. 113-118. 27. Isoniazid -CDC Tablet 300 mg/tab [Package insert]. March, 2016: Shinlon Pharmaceutical Ind. Co., Ltd, Tainan, ROC. 28. Peloquin, C.A., et al., Population pharmacokinetic modeling of isoniazid, rifampin, and pyrazinamide. Antimicrobial agents and chemotherapy, 1997. 41(12): p. 2670-2679. 29. Wang, P., et al., Isoniazid metabolism and hepatotoxicity. Acta Pharm Sin B, 2016. 6(5): p. 384-392. 30. Boxenbaum, H.G. and S. Riegelman, Determination of isoniazid and metabolites in biological fluids. J Pharm Sci, 1974. 63(8): p. 1191-7. 31. Hurwitz, A. and D.L. Schlozman, Effects of antacids on gastrointestinal absorption of isoniazid in rat and man. American Review of Respiratory Disease, 1974. 109(1): p. 41-47. 32. Priftin-CDC Tablet 150 mg/tab [Package insert]. November, 2014: Sanofi-Aventis U.S. LLC. 33. Alghamdi, W.A., M.H. Al-Shaer, and C.A. Peloquin, Protein binding of first-line antituberculosis drugs. Antimicrobial agents and chemotherapy, 2018. 62(7): p. e00641-18. 34. Isoniazid Tablets, USP [Package insert]. October, 2018: Sandoz Inc. 35. Roy, B., et al., Increased risk of antituberculosis drug‐induced hepatotoxicity in individuals with glutathione S‐transferase M1 ‘null’mutation. Journal of gastroenterology and hepatology, 2001. 16(9): p. 1033-1037. 36. Robson, J. and F. Sullivan, Antituberculosis drugs. Pharmacological reviews, 1963. 15(2): p. 169-223. 37. Holdiness, M.R., Clinical pharmacokinetics of the antituberculosis drugs. Clinical pharmacokinetics, 1984. 9(6): p. 511-544. 38. Mitchell, J.R., et al., Increased incidence of isoniazid hepatitis in rapid acetylators: possible relation to hydrazine metabolites. Clinical Pharmacology Therapeutics, 1975. 18(1): p. 70-79. 39. 江振源主編, 結核病診治指引 第六版. 2017: 衛生福利部疾病管制署. 40. Biehl, J.P. and R.W. Vilter, Effects of isoniazid on pyridoxine metabolism. Journal of the American Medical Association, 1954. 156(17): p. 1549-1552. 41. MITCHELL, J.R., et al., Isoniazid liver injury: clinical spectrum, pathology, and probable pathogenesis. Annals of internal medicine, 1976. 84(2): p. 181-192. 42. Nolan, C.M., S.V. Goldberg, and S.E. Buskin, Hepatotoxicity associated with isoniazid preventive therapy: a 7-year survey from a public health tuberculosis clinic. Jama, 1999. 281(11): p. 1014-1018. 43. Davis, R. and B. Stoler, Febrile reactions to INH. The New England journal of medicine, 1977. 297(6): p. 337-337. 44. Jacobs, N.F. and S.E. Thompson, Spiking fever from isoniazid simulating a septic process. JAMA, 1977. 238(16): p. 1759-1760. 45. Crook, M.J., Isoniazid-induced anaphylaxis. J Clin Pharmacol, 2003. 43(5): p. 545-6. 46. Product Information: Paser(TM), aminosalicylic acid. Jacobus Pharmaceutical Co., Inc., Princeton, NJ, 07/1996. 47. Weinstein L: Antimicrobial Agents, in Goodman LS, Gilman A (Eds): The Pharmacological Basis of Therapeutics, 4th ed. Macmillan, New York, 1970; 1320-1324. 48. Sarma, G.R., et al., Effect of prednisolone and rifampin on isoniazid metabolism in slow and rapid inactivators of isoniazid. Antimicrob Agents Chemother, 1980. 18(5): p. 661-6. 49. Sarma, G.R., et al., Rifampin-lnduced Release of Hydrazine from Isoniazid: A Possible Cause of Hepatitis during Treatment of Tuberculosis with Regimens Containing Isoniazid and Rifampin. American Review of Respiratory Disease, 1986. 133(6): p. 1072-1075. 50. Burman, W.J., K. Gallicano, and C. Peloquin, Comparative pharmacokinetics and pharmacodynamics of the rifamycin antibacterials. Clinical pharmacokinetics, 2001. 40(5): p. 327-341. 51. Keung, A., et al., Single and multiple dose pharmacokinetics of rifapentine in man: part II. The International Journal of Tuberculosis and Lung Disease, 1999. 3(5): p. 437-444. 52. Keung, A.C., et al., Pharmacokinetics of rifapentine in subjects seropositive for the human immunodeficiency virus: a phase I study. Antimicrobial agents and chemotherapy, 1999. 43(5): p. 1230-1233. 53. Reith, K., et al., Disposition and metabolism of 14C-rifapentine in healthy volunteers. Drug Metab Dispos, 1998. 26(8): p. 732-8. 54. ASSANDRI, A., B. RATTI, and T. CRISTINA, Pharmacokinetics of rifapentine, a new long lasting rifamycin, in the rat, the mouse and the rabbit. The Journal of antibiotics, 1984. 37(9): p. 1066-1075. 55. Conte, J.E., et al., Single-dose intrapulmonary pharmacokinetics of rifapentine in normal subjects. Antimicrobial agents and chemotherapy, 2000. 44(4): p. 985-990. 56. Nakajima, A., et al., Human arylacetamide deacetylase is responsible for deacetylation of rifamycins: rifampicin, rifabutin, and rifapentine. Biochemical pharmacology, 2011. 82(11): p. 1747-1756. 57. Rastogi, N., et al., Activity of rifapentine and its metabolite 25-O-desacetylrifapentine compared with rifampicin and rifabutin against Mycobacterium tuberculosis, Mycobacterium africanum, Mycobacterium bovis and M. bovis BCG. Journal of Antimicrobial Chemotherapy, 2000. 46(4): p. 565-570. 58. Strolin Benedetti, M. and P. Dostert, Induction and autoinduction properties of rifamycin derivatives: a review of animal and human studies. Environ Health Perspect, 1994. 102(suppl 9): p. 101-105. 59. Savic, R.M., et al., Population pharmacokinetics of rifapentine and desacetyl rifapentine in healthy volunteers: nonlinearities in clearance and bioavailability. Antimicrob Agents Chemother, 2014. 58(6): p. 3035-42. 60. Dooley, K., et al., Repeated administration of high-dose intermittent rifapentine reduces rifapentine and moxifloxacin plasma concentrations. Antimicrob Agents Chemother, 2008. 52(11): p. 4037-42. 61. Weiner, M., et al., Rifapentine Pharmacokinetics and Tolerability in Children and Adults Treated Once Weekly With Rifapentine and Isoniazid for Latent Tuberculosis Infection. J Pediatric Infect Dis Soc, 2014. 3(2): p. 132-45. 62. Bock, N.N., et al., A prospective, randomized, double-blind study of the tolerability of rifapentine 600, 900, and 1,200 mg plus isoniazid in the continuation phase of tuberculosis treatment. Am J Respir Crit Care Med, 2002. 165(11): p. 1526-30. 63. Schechter, M., et al., Weekly rifapentine/isoniazid or daily rifampin/pyrazinamide for latent tuberculosis in household contacts. Am J Respir Crit Care Med, 2006. 173(8): p. 922-6. 64. Brooks, K.M., et al., Cytokine-Mediated Systemic Adverse Drug Reactions in a Drug-Drug Interaction Study of Dolutegravir With Once-Weekly Isoniazid and Rifapentine. Clin Infect Dis, 2018. 67(2): p. 193-201. 65. Keung, A., et al., Enzyme induction observed in healthy volunteers after repeated administration of rifapentine and its lack of effect on steady-state rifapentine pharmacokinetics: part I. International Journal of Tuberculosis Lung Disease, 1999. 3(5): p. 426-436. 66. Li, A.P., et al., Primary human hepatocytes as a tool for the evaluation of structure—activity relationship in cytochrome P450 induction potential of xenobiotics: evaluation of rifampin, rifapentine and rifabutin. Chemico-biological interactions, 1997. 107(1-2): p. 17-30. 67. IBM Watson Health, G.V., Colorado, USA. IBM Micromedex® DRUGDEX® (electronic version). [cited 2020 May 26]; Available from: https://www.micromedexsolutions.com/. 68. Morrissey KM, W.C., Johns SJ, Zhang L, Huang SM, Giacomini KM, 'The UCSF-FDA TransPortal: A Public Drug Transporter Database'. Clinical Pharmacology and Therapeutics (2012) 92(5):545-6. 69. Fukino, K., et al., Effects of N-acetyltransferase 2 (NAT2), CYP2E1 and Glutathione-S-transferase (GST) genotypes on the serum concentrations of isoniazid and metabolites in tuberculosis patients. The Journal of toxicological sciences, 2008. 33(2): p. 187-195. 70. Ellard, G., Variations between individuals and populations in the acetylation of isoniazid and its significance for the treatment of pulmonary tuberculosis. Clinical Pharmacology Therapeutics, 1976. 19(5part2): p. 610-625. 71. Richardson, M., et al., NAT2 variants and toxicity related to anti-tuberculosis agents: a systematic review and meta-analysis. The International Journal of Tuberculosis and Lung Disease, 2019. 23(3): p. 293-305. 72. Yee, S.W., et al., Influence of transporter polymorphisms on drug disposition and response: a perspective from the international transporter consortium. Clinical Pharmacology and therapeutics, 2018. 104(5): p. 803-817. 73. Hein, D.W., et al., Metabolic activation of N-hydroxyarylamines and N-hydroxyarylamides by 16 recombinant human NAT2 allozymes: effects of 7 specific NAT2 nucleic acid substitutions. Cancer research, 1995. 55(16): p. 3531-3536. 74. Boukouvala, S. Human NAT2 Alleles (Haplotypes). 18/04/2016 [cited 2020 06/02]; Available from: http://nat.mbg.duth.gr/Human%20NAT2%20alleles_2013.htm. 75. (PharmGKB), P.K. NAT2. [cited 2020 06/02]; Available from: https://www.pharmgkb.org/gene/PA18. 76. Cascorbi, I., et al., Arylamine N-acetyltransferase (NAT2) mutations and their allelic linkage in unrelated Caucasian individuals: correlation with phenotypic activity. American journal of human genetics, 1995. 57(3): p. 581. 77. Agúndez, J.A., et al., Identification and prevalence study of 17 allelic variants of the human NAT2 gene in a white population. Pharmacogenetics, 1996. 6(5): p. 423-428. 78. Sabbagh, A., et al., Arylamine N-acetyltransferase 2 (NAT2) genetic diversity and traditional subsistence: a worldwide population survey. PloS one, 2011. 6(4): p. e18507. 79. Chen, B., W.-X. Zhang, and W.-M. Cai, The influence of various genotypes on the metabolic activity of NAT2 in a Chinese population. European journal of clinical pharmacology, 2006. 62(5): p. 355-359. 80. Lee, S., et al., NAT2 and CYP2E1 polymorphisms and susceptibility to first-line anti-tuberculosis drug-induced hepatitis. The International Journal of Tuberculosis and Lung Disease, 2010. 14(5): p. 622-626. 81. Chang, C.-H., et al., N-Acetyltransferase 2 (NAT2) genetic variation and the susceptibility to noncardiac gastric adenocarcinoma in Taiwan. Journal of the Chinese Medical Association, 2016. 79(3): p. 105-110. 82. Kinzig-Schippers, M., et al., Should we use N-acetyltransferase type 2 genotyping to personalize isoniazid doses? Antimicrobial agents and chemotherapy, 2005. 49(5): p. 1733-1738. 83. Short, E.I., Studies on the inactivation of isonicotinyl acid hydrazide in normal subjects and tuberculous patients. Tubercle, 1962. 43(1): p. 33-42. 84. Kubota, R., et al., Dose-escalation study of isoniazid in healthy volunteers with the rapid acetylator genotype of arylamine N-acetyltransferase 2. European journal of clinical pharmacology, 2007. 63(10): p. 927-933. 85. Parvez, M.M., et al., Comprehensive Substrate Characterization of 22 Antituberculosis Drugs for Multiple Solute Carrier (SLC) Uptake Transporters In Vitro. Antimicrob Agents Chemother, 2018. 62(9): p. e00512-18. 86. Yee, S.W., et al., Reduced renal clearance of cefotaxime in asians with a low-frequency polymorphism of OAT3 (SLC22A8). Journal of pharmaceutical sciences, 2013. 102(9): p. 3451-3457. 87. L. Phan, Y.J., H. Zhang, W. Qiang, E. Shekhtman, D. Shao, D. Revoe, R. Villamarin, E. Ivanchenko, M. Kimura, Z. Y. Wang, L. Hao, N. Sharopova, M. Bihan, A. Sturcke, M. Lee, N. Popova, W. Wu, C. Bastiani, M. Ward, J. B. Holmes, V. Lyoshin, K. Kaur, E. Moyer, M. Feolo, and B. L. Kattman. ALFA: Allele Frequency Aggregator. [cited 2020 10 Mar.]; Available from: www.ncbi.nlm.nih.gov/snp/docs/gsr/alfa/. 88. Wang, Z.-J., et al., OCT2 polymorphisms and in-vivo renal functional consequence: studies with metformin and cimetidine. Pharmacogenetics and Genomics, 2008. 18(7): p. 637-645. 89. Shimizu, M., et al., A novel polymorphic allele of human arylacetamide deacetylase leads to decreased enzyme activity. Drug Metabolism and Disposition, 2012. 40(6): p. 1183-1190. 90. Francis, J., et al., A population pharmacokinetic analysis shows that arylacetamide deacetylase (AADAC) gene polymorphism and HIV infection affect the exposure of rifapentine. Antimicrobial agents and chemotherapy, 2019. 63(4): p. e01964-18. 91. Vavricka, S.R., et al., Interactions of rifamycin SV and rifampicin with organic anion uptake systems of human liver. Hepatology, 2002. 36(1): p. 164-172. 92. Chew, S.-C., et al., The effects of CYP3A4, CYP3A5, ABCB1, ABCC2, ABCG2 and SLCO1B3 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of docetaxel in nasopharyngeal carcinoma patients. Cancer chemotherapy pharmacology, 2011. 67(6): p. 1471-1478. 93. de Graan, A.-J.M., et al., Influence of polymorphic OATP1B-type carriers on the disposition of docetaxel. Clinical Cancer Research, 2012. 18(16): p. 4433-4440. 94. Kiang, T.K., et al., Fundamentals of population pharmacokinetic modelling. Clinical pharmacokinetics, 2012. 51(8): p. 515-525. 95. Population Pharmacokinetics. 10/24/2019, Food and Drug Administration. 96. Monolix version 2019R2. [cited 2020; Available from: http://lixoft.com/products/monolix/. 97. Sundell, J., et al., Model-Based Assessment of Variability in Isoniazid Pharmacokinetics and Metabolism in Patients Co-Infected With Tuberculosis and HIV: Implications for a Novel Dosing Strategy. Clin Pharmacol Ther, 2020. 98. Seng, K.-Y., et al., Population pharmacokinetic analysis of isoniazid, acetylisoniazid, and isonicotinic acid in healthy volunteers. Antimicrob Agents Chemother, 2015. 59(11): p. 6791-6799. 99. Wilkins, J.J., et al., Variability in the population pharmacokinetics of isoniazid in South African tuberculosis patients. Br J Clin Pharmacol, 2011. 72(1): p. 51-62. 100. Langdon, G., et al., Population pharmacokinetics of rifapentine and its primary desacetyl metabolite in South African tuberculosis patients. Antimicrob Agents Chemother, 2005. 49(11): p. 4429-36. 101. Zvada, S.P., et al., Effects of four different meal types on the population pharmacokinetics of single-dose rifapentine in healthy male volunteers. Antimicrob Agents Chemother, 2010. 54(8): p. 3390-4. 102. Cockcroft, D.W. and M.H. Gault, Prediction of creatinine clearance from serum creatinine. Nephron, 1976. 16(1): p. 31-41. 103. Chen, L.-I., et al., Modification of diet in renal disease (MDRD) study and CKD epidemiology collaboration (CKD-EPI) equations for Taiwanese adults. PloS one, 2014. 9(6): p. e99645. 104. University of Louisville, KY, USA. Department of Pharmacology and Toxicology.; Available from: http://louisville.edu/medicine/departments/pharmacology/news-information/nat. 105. Wählby, U., E.N. Jonsson, and M.O. Karlsson, Comparison of stepwise covariate model building strategies in population pharmacokinetic-pharmacodynamic analysis. AAPS PharmSci, 2002. 4(4): p. 68-79. 106. Retlich, S., et al., Population Pharmacokinetics and Pharmacodynamics of Linagliptin in Patients with Type 2 Diabetes Mellitus. Clin Pharmacokinet, 2015. 54(7): p. 737-50. 107. Bertrand, J. and F. Mentré. Mathematical expressions of the pharmacokinetic and pharmacodynamic models implemented in the Monolix software. 2008; Available from: http://lixoft.com/wp-content/uploads/2016/03/PKPDlibrary.pdf. 108. Lea-Henry, T.N., et al., Clinical pharmacokinetics in kidney disease: Fundamental principles. Clinical journal of the American society of nephrology, 2018. 13(7): p. 1085-1095. 109. Naud, J., et al., Current understanding of drug disposition in kidney disease. Journal of Clinical Pharmacology, 2012. 52(S1): p. 10S-22S. 110. Jing, W., et al., Population Pharmacokinetic Analysis of Isoniazid among Pulmonary Tuberculosis Patients from China. Antimicrob Agents Chemother, 2020. 64(3). 111. Denti, P., et al., Pharmacokinetics of isoniazid, pyrazinamide, and ethambutol in newly diagnosed pulmonary TB patients in Tanzania. PloS one, 2015. 10(10): p. e0141002. 112. Jones, A.E., et al., Variability in drug metabolizing enzyme activity in HIV-infected patients. European journal of clinical pharmacology, 2010. 66(5): p. 475-485. 113. Liu, Z., et al., Elevated CD38 antigen expression on CD8+ T cells is a stronger marker for the risk of chronic HIV disease progression to AIDS and death in the Multicenter AIDS Cohort Study than CD4+ cell count, soluble immune activation markers, or combinations of HLA-DR and CD38 expression. J Acquir Immune Defic Syndr Hum Retrovirol, 1997. 16(2): p. 83-92. 114. Kolber, M.A., et al., Intensification of a suppressive HAART regimen increases CD4 counts and decreases CD8+ T-cell activation. Clinical Immunology, 2008. 126(3): p. 315-321. 115. Vinnard, C., et al., Isoniazid clearance is impaired among human immunodeficiency virus/tuberculosis patients with high levels of immune activation. British journal of clinical pharmacology, 2017. 83(4): p. 801-811. 116. Nolin, T.D., R.F. Frye, and G.R. Matzke, Hepatic drug metabolism and transport in patients with kidney disease. Am J Kidney Dis, 2003. 42(5): p. 906-925. 117. Yeung, C.K., et al., Effects of chronic kidney disease and uremia on hepatic drug metabolism and transport. Kidney Int., 2014. 85(3): p. 522-528. 118. Simard, E., et al., Downregulation of hepatic acetylation of drugs in chronic renal failure. J Am Soc Nephrol, 2008. 19(7): p. 1352-1359. 119. Prokopienko, A.J. and T.D. Nolin, Microbiota-derived uremic retention solutes: perpetrators of altered nonrenal drug clearance in kidney disease. Expert review of clinical pharmacology, 2018. 11(1): p. 71-82. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/18831 | - |
dc.description.abstract | 簡介 潛伏結核感染是一種結核菌長期存在於宿主體內,使宿主持續產生免疫反應的狀態。潛伏結核感染者沒有症狀,但終生都有可能發展為活動性結核。為了達成世界衛生組織(World Health Organization, WHO)2035年結核盛行率降低至每十萬人口10例以下的目標,針對尚未發病的個案給予潛伏結核感染治療是重要的疾病防治策略。速克伏(3HP)為每週一次isoniazid合併rifapentine總計12週之短程處方(依體重調整劑量,成人劑量約600-900 mg),其優勢在於短期療程之服藥順從性高,肝毒性發生率較傳統處方低,但近年研究發現病人容易發生全身性藥物反應副作用,影響藥物血中濃度或分布代謝個體間變異的共變項是否扮演重要角色有待釐清,且目前缺乏針對臺灣潛伏結核族群使用3HP的族群藥動學模型。因此本研究旨在探討臺灣潛伏結核族群高劑量isoniazid與rifapentine之藥動參數及影響藥動參數個體間差異的共變項,做為未來臨床分析之基礎。 方法 本研究為前瞻、觀察性研究,研究對象為2017年10月至2019年10月使用3HP做為潛伏結核感染預防性治療之成年人。Isoniazid與rifapentine抽血時間為服藥後3, 6, 24, 48小時,受試者血中藥物濃度採用超高效液相層析串聯質譜分析,並使用nonlinear mixed effects model (Monolix software, 2019R2)估算受試者藥動學參數。由於本研究藥物於吸收相濃度資料不足,因此採用文獻之吸收速率常數與吸收延遲情形並從中選出最適合者固定(fixed)於本研究模型;isoniazid與rifapentine皆採用一級線性吸收與排除建立模型,尋找最適當的個體間、個體內、場合間變異模型,並分析臨床共變項、共病症、肝腎功能、併用藥物、藥物代謝酵素或運輸蛋白基因多型性與藥動參數的相關性。 結果 本研究共納入35名潛伏結核感染者,其中29名來自臺大醫院,6名來自臺大醫院雲林分院,年齡中位數52歲(24-75歲),體重中位數64.4公斤(42-93公斤),含男性18名與女性17名,總計77筆濃度資料。 Isoniazid模型為一級吸收與一級排除速率之二室模型,個體內變異以常數型(constant),擬似分布體積與擬似清除率個體間變異以指數型(exponential)最能夠描述本研究之濃度資料。群體中央室擬似分布體積為141 L,年齡為顯著影響的共變項,加入模型後中央室擬似分布體積之個體間變異從56.5%下降至15.9%,年齡越大則中央室擬似分布體積越大,呈正相關。群體清除率為95.6 L/h,NAT2表現型與是否洗腎是影響isoniazid清除率的2個重要共變項,清除率個體間差異從94%下降至45.5%。NAT2慢速乙醯代謝者之isoniazid清除率約為快速與中等乙醯代謝者的26.4%;洗腎患者(服藥、抽血日與洗腎日間隔)之isoniazid清除率為非洗腎者的35.7%。 Rifapentine模型為一級吸收與一級排除速率之一室模型,個體內變異以常數型(constant),擬似分布體積個體間變異以指數型(exponential),清除率個體間變異以疊加型(additive)描述最佳。群體擬似分布體積為29.5 L,真實體重以及是否為洗腎病人是顯著影響的共變項,其中體重與擬似分布體積呈正相關,洗腎者擬似分布體積為非洗腎者之1.69倍,將此二共變項加入模型後rifapentine擬似分布體積個體間變異從55.7%下降至33.3%。群體清除率為0.929 L/h,於藥動模型中沒有發現顯著影響的共變項。進行多變項迴歸分析發現代謝酵素AADAC rs1803155 GG genotype與清除率較高相關,服用steroids與清除率較低相關。 結論 本研究建立臺灣潛伏結核感染族群使用高劑量isoniazid與rifapentine藥動學模型,發現年齡顯著影響isoniazid中央室擬似分布體積,NAT2表現型與是否洗腎顯著影響isoniazid清除率;體重與是否洗腎顯著影響rifapentine擬似分布體積。本研究以族群藥動學的角度指出重度腎功能不全對原本並非以腎臟為主要代謝或排除途徑的藥物產生藥動學的變化。 關鍵字 Isoniazid、rifapentine、潛伏結核感染、族群藥動學、Monolix | zh_TW |
dc.description.abstract | Introduction Latent tuberculosis infection (LTBI) is a state of positive immune response to stimulation by Mycobacterium tuberculosis antigens without evidence of clinically manifested active TB. The World Health Organization (WHO) has established the goal of tuberculosis (TB) elimination (incidence rate < 10 per 100,000 populations) by 2035. Therefore, providing preventive therapy for LTBI individuals is important. 3HP regimen containing 12 doses of isoniazid (INH) and rifapentine (RPT) is recommended to prevent the development of active TB. It demonstrated lower incidence of hepatotoxicity but higher incidence of systemic drug reactions (SDR). Whether the drug concentrations or the factors affecting the variability in pharmacokinetics (PK) among individuals play an important role remain uncertain. In addition, PK of 3HP are not fully described in Taiwanese. Therefore, this study aimed to characterize the population PK of 3HP in Taiwanese LTBI participants. Method Adult participants who diagnosed with LTBI and received 3HP were enrolled prospectively from October 2017 to October 2019. Plasma INH and RPT concentrations were drawn at 3, 6, 24 and 48 hours after dose administration, and analyzed by liquid chromatography with tandem mass spectrometry. Pharmacokinetic data of INH and RPT were analyzed using nonlinear mixed effects model in Monolix software (version 2019R2) to estimate population pharmacokinetics. The absorption rate constant (Ka) and absorption lag time were fixed according to the values from literature due to the lack of absorption information in our data. One- and two-compartment disposition models with first-order absorption and elimination were used to describe the PK of INH and RPT, respectively. Suitable models for inter-individual variability, intra-individual variability, and inter-occasion variability were tested to describe the residual errors. The effects of potential covariates such as demographics and clinical characteristics, concomitant diseases, liver and kidney laboratory tests, co-medication, genetic polymorphisms of metabolic enzymes and transporters were evaluated. Result A total of 35 subjects were enrolled and contributed 77 plasma concentrations. The median age and weight of the subjects were 52 years (range, 24 to 75 years) and 64.4 kg (range, 42 to 93 kg), respectively; 17 of the 35 subjects were female. The population PK of INH were best described by a two-compartment model with first-order elimination and first-order absorption. Residual and inter-individual variabilities were described as constant and exponential error models, respectively. The value of apparent central volume of distribution (Vc) was 141 L. Age for allometric scaling on Vc was identified as a significant covariate, reducing the interindividual variability from 56.5% to 15.9%. Subjects who were older were associated with larger Vc. The value of clearance (CL) was 95.6 L/h. NAT2 phenotype and dialysis were confirmed as significant covariates, reducing the interindividual variability from 94% to 45.5%. Slow acetylators were associated with a 73.6% lower CL compared with rapid and intermediate acetylators, and patients who were under dialysis were found to have a 64.3% lower CL. The population PK of RPT were well described by a one-compartment model with first-order elimination and first-order absorption with a lag time. Residual was described as constant error model. Inter-individual variabilities of apparent volume of distribution (V) and CL were described as exponential and additive error models, respectively. The value of V was 29.5 L. Total body weight (via allometric scaling) and dialysis significantly affected RPT V, reducing the interindividual variability from 55.7% to 33.3%. Patients with higher weight were associated with larger V, and patients who were under dialysis were found to had a 1.69-fold higher V. The value of CL was 0.929 L/h. Factors responsible for the variability in RPT CL was not found in the study. In stepwise multivariate regression analysis, factors independently associated with CL included AADAC rs1803155 GG genotype (coefficient 0.27; 95% confidence interval [CI], 0.13, 0.42; p=0.0003) and receipt of steroids (coefficient -0.21; 95% CI, -0.39, -0.03; p=0.02). Conclusion We developed a population pharmacokinetic model for high dose INH and RPT in Taiwan. In the INH model, age explained the variability in INH Vc, while NAT2 phenotype status and dialysis significantly affect the variability in INH clearance. In the RPT model, weight and dialysis had a major impact on V. This study pointed out that severe renal insufficiency had significant impact on drug distribution and metabolism from the population pharmacokinetics perspective. Key words Isoniazid, rifapentine, latent tuberculosis infection, population pharmacokinetics, Monolix | en |
dc.description.provenance | Made available in DSpace on 2021-06-08T01:29:24Z (GMT). No. of bitstreams: 1 U0001-1008202020080700.pdf: 7452591 bytes, checksum: e2c2a5f9b3504d6f12b1238ee5263a8c (MD5) Previous issue date: 2020 | en |
dc.description.tableofcontents | 論文口試委員會審定書 i 誌謝 ii 中文摘要 iii Abstract vi 目錄 ix 圖目錄 xiii 表目錄 xv 第一章 前言 1 第二章 文獻回顧與探討 2 2.1 潛伏結核感染 2 2.1.1 潛伏結核感染簡介 2 2.1.2 潛伏結核感染治療處方 2 2.1.3 3HP處方 3 2.2 藥物介紹 3 2.2.1 Isoniazid 簡介 3 2.2.1.1 藥理機轉 4 2.2.1.2 藥品動態學(Pharmacokinetics) 4 2.2.1.3 副作用 5 2.2.1.4 藥物交互作用 6 2.2.2 Rifapentine 簡介 7 2.2.2.1 藥理機轉 7 2.2.2.2 藥品動態學(Pharmacokinetics) 7 2.2.2.3 副作用 8 2.2.2.4 藥物交互作用 8 2.3 藥物代謝酵素與運輸蛋白之基因多型性 9 2.3.1 Isoniazid 9 2.3.1.1 NAT2 9 2.3.1.2 OAT3 10 2.3.1.3 OCT2 10 2.3.2 Rifapentine 11 2.3.2.1 AADAC 11 2.3.2.2 OATP1B3 11 2.4 族群藥動學 12 第三章 研究目的 28 第四章 研究方法 29 4.1 研究架構 29 4.2 研究對象及地點 29 4.3 納入及排除條件 29 4.4 資料收集 30 4.4.1 基本資料 30 4.4.2 藥物劑量、服藥方式及抽血時間 30 4.5 實驗室分析 31 4.5.1 血中藥物濃度檢測 31 4.5.2 基因型分析 32 4.5.2.1 樣品前處理與DNA萃取 32 4.5.2.2 基因型分析與定序 32 4.6 族群藥動學 34 4.6.1 藥動學參數分析 34 4.6.2 基礎模型建立 34 4.6.3 共變項(covariate)分析 35 4.6.4 模型評估 36 4.7 統計方法 36 第五章 研究結果 46 5.1 受試者特性 46 5.2 INH藥動學資料與模型建立 47 5.2.1 INH血中濃度 47 5.2.2 INH基礎模型 47 5.2.3 影響INH藥動學的共變項 47 5.2.3.1 與中央室分佈體積Vc相關的共變項 47 5.2.3.2 與CL相關的共變項 48 5.2.4 INH最終模型 48 5.3 RPT藥動學資料與模型建立 50 5.3.1 RPT血中濃度 50 5.3.2 RPT基礎模型 50 5.3.3 影響RPT藥動學的共變項 51 5.3.3.1 與V相關的共變項 51 5.3.3.2 與CL相關的共變項 51 5.3.4 RPT最終模型 52 5.3.5 RPT線性迴歸分析 52 第六章 討論 148 6.1 受試者特性與資料特性 148 6.2 INH族群藥動學與其他研究的比較 148 6.3 RPT族群藥動學與其他研究的比較 151 6.4限制與未來展望 153 第七章 結論 154 第八章 參考文獻 155 | |
dc.language.iso | zh-TW | |
dc.title | 3HP處方之Isoniazid與Rifapentine用於治療潛伏結核感染之群體藥動學研究 | zh_TW |
dc.title | Population Pharmacokinetics of Weekly Isoniazid and Rifapentine for Latent Tuberculosis Infection | en |
dc.type | Thesis | |
dc.date.schoolyear | 108-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 樹金忠(Chin-Chung Shu),林君榮(Chun-Jung Lin),何蕴芳(Yunn-Fang Ho),郭錦樺(Ching-Hua Kuo) | |
dc.subject.keyword | isoniazid,rifapentine,潛伏結核感染,族群藥動學,Monolix, | zh_TW |
dc.subject.keyword | isoniazid,rifapentine,latent tuberculosis infection,population pharmacokinetics,Monolix, | en |
dc.relation.page | 162 | |
dc.identifier.doi | 10.6342/NTU202002868 | |
dc.rights.note | 未授權 | |
dc.date.accepted | 2020-08-12 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 臨床藥學研究所 | zh_TW |
顯示於系所單位: | 臨床藥學研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
U0001-1008202020080700.pdf 目前未授權公開取用 | 7.28 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。